A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the effect of tasisulam as an inhibitor of CYP2C9,
using tolbutamide as a probe substrate. This study was to have 3 treatment periods, and
continued access in an extension period. Period 1 is 4 days in length. Periods 2 and 3 are
each approximately 28 days in length. Due to the early termination of the trial, only 1
Period 3 participant enrolled in the extension period before study termination.